Implementation and Uptake of Raltegravir Granules in Newborns Diagnosed with HIV Through Birth Testing in Maternity Settings in Zimbabwe during the COVID-19 Pandemic
Pediatric Infectious Disease Journal, Volume 42, No. 7, Year 2023
Notification
URL copied to clipboard!
Zimbabwe introduced raltegravir (RAL) granules at 14 facilities providing point-of-care HIV birth testing, aiming to initiate all newborns with HIV on a RAL-based regimen. From June 2020 to July 2021, we tested 3172 of the 6989 (45%) newborns exposed to HIV; we diagnosed 59(2%) with HIV infection, of whom 27 (46%) initiated RAL. The SARS-CoV-2 coronavirus disease pandemic exacerbated supply chain and trained provider shortages, contributing to low birth testing, RAL uptake and 6-month viral load testing.